Su1006 Risk of Relapse After Azathioprine (AZA) Discontinuation in Inflammatory Bowel Disease (IBD) Patients in Maintained Remission

The effects of withdrawal of immunosuppressant therapy in people with quiescent Crohn's disease are uncertain. Low quality evidence suggests that continuing azathioprine monotherapy may be superior to withdrawal for avoiding clinical relapse, while very low quality evidence suggests that there may be no difference in clinical relapse rates between discontinuing azathioprine from a combination therapy regimen, compared to continuing combination therapy. It is unclear whether withdrawal of azathioprine, initially administered alone or in combination, impacts on the development of CD-related complications, adverse events, serious adverse events or withdrawal due to adverse events. Further high-quality research is needed in this area, particularly double-blind RCTs in which biologic therapy or an immunosuppressant other than azathioprine is withdrawn.

show abstract

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease

Boyapati

Torres

Palmela

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Su1006 Risk of Relapse After Azathioprine (AZA) Discontinuation in Inflammatory Bowel Disease (IBD) Patients in Maintained Remission

Cited by 1 publication

References 0 publications

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease

Contact Info

Product

Resources

About